Loading…
DXM Abuse Prevention Act of 2016
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 3,548 other S bills in the 114th — cohort avg 43d
DXM Abuse Prevention Act of 2016 This bill amends the Federal Food, Drug, and Cosmetic Act to prohibit the sale of a drug containing dextromethorphan (DXM) to an individual under age 18 unless the individual has a prescription or is actively enrolled in the military. Civil monetary penalties that escalate upon repeated violation are imposed. To possess or receive unfinished DXM, a person must be registered with the Department of Health and Human Services as a producer of a drug or medical device or otherwise allowed to engage in the practice of pharmacy, pharmaceutical production, or manufacture or distribution of drug ingredients. Unfinished DXM may be distributed only to these authorized persons. Common carriers distributing unfinished DXM between authorized persons are exempted. Civil monetary penalties are imposed for possession and distribution violations.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (5)
2016 · fourth_quarter · Health Issues
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
- H 2, "Medicare Access and CHIP Reauthorization Act of 2015", regarding all provisions. - HR 1078, "Food and Drug Administration Safety Over Sequestration Act of 2015", regarding all provisions. - S 1622, "FDA Device Accountability Act of 2015", regarding all provisions. - HR 6, "21st Century Cures Act", regarding all provisions. - S 993, "Comprehensive Justice and Mental Health Act of 2015", regarding all provisions. - Issues related to physician-owned companies that manufacture or distribute medical devices. - Issues relating to cosmetic regulatory reform. - Issues related to 340B payments to hospitals. - Issues related to pseudoephedrine. - Issues related to dextromethorphan. - Issues related to legislation that would modify the Medicare Part B drug reimbursement program. - Issues related to legislation that would establish a rebate in the Medicare Part D program. - Issues related to Pub.L. 108-164, "Fairness to Contact Lens Consumers Act" (FCLCA) and related FTC Contact Lens Rule. - S.2977, "The Medical Electronic Data Technology Enhancement for Consumers' Health" (MEDTECH Act), regarding all provisions. - H.R. 3250, "DXM Abuse Prevention Act of 2015", regarding all provisions. - S. 2994, "DXM Abuse Prevention Act of 2016", regarding all provisions. - S. 1767, "The Combination Products Regulatory Fairness Act of 2015", regarding all provisions. - HR 2646, "Helping Families in Mental Health Crisis Act of 2015", regarding all provisions. - HR 1854, "Comprehensive Justice and Mental Health Act of 2015", regarding all provisions. - S. 1014, "Personal Care Products Safety Act", regarding all provisions. - S. 2777, "Contact lens Consumer Health Protection Act of 2016", regarding all provisions. - Issues related to Medicare Part B Demo - Issues related to Expanded Access in Senate Innovation Package - Issues related to Self monitoring of blood glucose meters. - HR 4075, "Cosmetic Modernization Amendments of 2015", regarding all provisions. - HR 1192, "National Clinical Care Commission Act", regarding all provisions.
Client expense: $1,460,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
2016 · fourth_quarter · Pharmacy
H.R.3250/S. 2994 - DXM Abuse Prevention Act of 2015 H.R. 1270 / S. 620 - Restore Access to Medication Act H.R. 592 / S. 314 - Pharmacy and Medically Underserved Areas Enhancement Act H.R.3762 - Restoring Americans' Healthcare Freedom Reconciliation Act of 2015 H.R. 793/S. 1190 - the Ensuring Seniors Access to Local Pharmacies Act Health Savings Act of 2016 - H.R.4469/S.2499 H.R. 5951/S. 3308 - Improving Transparency and Accuracy in Medicare Part D Spending Act
Client expense: $100,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Health Issues
- H.R. 1078, Food and Drug Administration Safety Over Sequestration Act of 2015, regarding all provisions. - H.R. 6 - 21st Century Cures Act (P.L. 114-255), regarding all provisions. - Issues relating to cosmetic regulatory reform. - Issues related to pseudoephedrine. - Issues related Fairness to Contact Lens Consumers Act (P.L. 108-164) and related FTC Contact Lens Rule. - H.R. 3250 - DXM Abuse Prevention Act of 2015, regarding all provisions. - S. 2994 - DXM Abuse Prevention Act of 2016, regarding all provisions. - S. 1014 - Personal Care Products Safety Act of 2015, regarding all provisions. - S. 277 - Contact lens Consumer Health Protection Act of 2016, regarding all provisions. - S 697 - Frank R. Lautenberg Chemical Safety for the 21st Century Act, regarding all provisions. - H.R. 2858 - Humane Cosmetics Act, regarding all provisions.
Client expense: Not reported · Firm income: $45,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Health Issues
- H.R. 1078, Food and Drug Administration Safety Over Sequestration Act of 2015, regarding all provisions. - H.R. 6 - 21st Century Cures Act (P.L. 114-255), regarding all provisions. - Issues relating to cosmetic regulatory reform. - Issues related to pseudoephedrine. - Issues related Fairness to Contact Lens Consumers Act (P.L. 108-164) and related FTC Contact Lens Rule. - H.R. 3250 - DXM Abuse Prevention Act of 2015, regarding all provisions. - S. 2994 - DXM Abuse Prevention Act of 2016, regarding all provisions. - S. 1014 - Personal Care Products Safety Act of 2015, regarding all provisions. - S. 277 - Contact lens Consumer Health Protection Act of 2016, regarding all provisions. - S 697 - Frank R. Lautenberg Chemical Safety for the 21st Century Act, regarding all provisions. - H.R. 2858 - Humane Cosmetics Act, regarding all provisions.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Health Issues
- H.R. 1078, Food and Drug Administration Safety Over Sequestration Act of 2015, regarding all provisions. - H.R. 6 - 21st Century Cures Act (P.L. 114-255), regarding all provisions. - Issues relating to cosmetic regulatory reform. - Issues related to pseudoephedrine. - Issues related Fairness to Contact Lens Consumers Act (P.L. 108-164) and related FTC Contact Lens Rule. - H.R. 3250 - DXM Abuse Prevention Act of 2015, regarding all provisions. - S. 2994 - DXM Abuse Prevention Act of 2016, regarding all provisions. - S. 1014 - Personal Care Products Safety Act of 2015, regarding all provisions. - S. 277 - Contact lens Consumer Health Protection Act of 2016, regarding all provisions. - S 697 - Frank R. Lautenberg Chemical Safety for the 21st Century Act, regarding all provisions. - H.R. 2858 - Humane Cosmetics Act, regarding all provisions.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Alcohol and Drug Abuse
Dextromethorphan H.R. 3250/S. 2994, the "DXM Abuse Prevention Act" (DAP) - legislation that would ban the sale of over-the-counter cough and cold medications containing the active ingredient dextromethorphan (DXM) to minors under the age of 18. Additionally, would ban the sale of bulk, unfinished DXM to entities not registered with the U.S. Food and Drug Administration; all sections.
Client expense: $370,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
2016 · fourth_quarter · Alcohol and Drug Abuse
Issues related to the sale of medicines that contain dextromethorphan, including H.R.3250 and S.2994, the DXM Abuse Prevention Act.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Pharmacy
H.R.3250/S. 2994 - DXM Abuse Prevention Act of 2015 H.R. 1270 / S. 620 - Restore Access to Medication Act H.R. 592 / S. 314 - Pharmacy and Medically Underserved Areas Enhancement Act H.R. 2029 - Consolidated Appropriations Act, House Amendments 1 and 2 to Senate Amendment published as Rules Committee Prints 114-39 and 114-40 H.R.3762 - Restoring Americans' Healthcare Freedom Reconciliation Act of 2015 H.R. 793/S. 1190 - the Ensuring Seniors Access to Local Pharmacies Act Health Savings Act of 2016 - H.R.4469/S.2499 H.R. 5951/S. 3308 - Improving Transparency and Accuracy in Medicare Part D Spending Act
Client expense: $150,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Health Issues
- H 2, "Medicare Access and CHIP Reauthorization Act of 2015", regarding all provisions. - HR 1078, "Food and Drug Administration Safety Over Sequestration Act of 2015", regarding all provisions. - S 1622, "FDA Device Accountability Act of 2015", regarding all provisions. - HR 6, "21st Century Cures Act", regarding all provisions. - S 993, "Comprehensive Justice and Mental Health Act of 2015", regarding all provisions. - Issues related to physician-owned companies that manufacture or distribute medical devices. - Issues relating to cosmetic regulatory reform. - Issues related to 340B payments to hospitals. - Issues related to pseudoephedrine. - Issues related to dextromethorphan. - Issues related to legislation that would modify the Medicare Part B drug reimbursement program. - Issues related to legislation that would establish a rebate in the Medicare Part D program. - Issues related to Pub.L. 108-164, "Fairness to Contact Lens Consumers Act" (FCLCA) and related FTC Contact Lens Rule. - S.2977, "The Medical Electronic Data Technology Enhancement for Consumers' Health" (MEDTECH Act), regarding all provisions. - H.R. 3250, "DXM Abuse Prevention Act of 2015", regarding all provisions. - S. 2994, "DXM Abuse Prevention Act of 2016", regarding all provisions. - S. 1767, "The Combination Products Regulatory Fairness Act of 2015", regarding all provisions. - HR 2646, "Helping Families in Mental Health Crisis Act of 2015", regarding all provisions. - HR 1854, "Comprehensive Justice and Mental Health Act of 2015", regarding all provisions. - S. 1014, "Personal Care Products Safety Act", regarding all provisions. - S. 277, "Contact lens Consumer Health Protection Act of 2016", regarding all provisions. - Issues related to Medicare Part B Demo - Issues related to Expanded Access in Senate Innovation Package - Issues related to Self monitoring of blood glucose meters. - HR 4075, "Cosmetic Modernization Amendments of 2015", regarding all provisions.
2016 · third_quarter · Health Issues
- HR 1078, "Food and Drug Administration Safety Over Sequestration Act of 2015", regarding all provisions. - HR 6, "21st Century Cures Act", regarding all provisions. - Issues relating to cosmetic regulatory reform. - Issues related to pseudoephedrine. - Issues related to Pub.L. 108-164, "Fairness to Contact Lens Consumers Act" (FCLCA) and related FTC Contact Lens Rule. - H.R. 3250, "DXM Abuse Prevention Act of 2015", regarding all provisions. - S. 2994, "DXM Abuse Prevention Act of 2016", regarding all provisions. - S. 1014, "Personal Care Products Safety Act", regarding all provisions. - S. 277, "Contact lens Consumer Health Protection Act of 2016", regarding all provisions. - S 697, "Frank R. Lautenberg Chemical Safety for the 21st Century Act", regarding all provisions. - HR 2858, "Humane Cosmetics Act", regarding all provisions.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Alcohol and Drug Abuse
Issues related to the sale of medicines that contain dextromethorphan, including H.R.3250 and S.2994, the DXM Abuse Prevention Act.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Alcohol and Drug Abuse
Dextromethorphan H.R. 3250/S. 2994, the "DXM Abuse Prevention Act" (DAP) - legislation that would ban the sale of over-the-counter cough and cold medications containing the active ingredient dextromethorphan (DXM) to minors under the age of 18. Additionally, would ban the sale of bulk, unfinished DXM to entities not registered with the U.S. Food and Drug Administration; all sections.
Client expense: $290,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
2016 · second_quarter · Pharmacy
H.R.3250/S. 2994 - DXM Abuse Prevention Act of 2015 H.R. 1270 / S. 620 - Restore Access to Medication Act H.R. 592 / S. 314 - Pharmacy and Medically Underserved Areas Enhancement Act H.R. 2029 - Consolidated Appropriations Act, House Amendments 1 and 2 to Senate Amendment published as Rules Committee Prints 114-39 and 114-40 H.R.3762 - Restoring Americans' Healthcare Freedom Reconciliation Act of 2015 H.R. 793/S. 1190 - the Ensuring Seniors Access to Local Pharmacies Act Health Savings Act of 2016 - H.R.4469/S.2499
Client expense: $280,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · second_quarter · Health Issues
- H 2, "Medicare Access and CHIP Reauthorization Act of 2015", regarding all provisions. - HR 1078, "Food and Drug Administration Safety Over Sequestration Act of 2015", regarding all provisions. - S 1622, "FDA Device Accountability Act of 2015", regarding all provisions. - HR 6, "21st Century Cures Act", regarding all provisions. - S 993, "Comprehensive Justice and Mental Health Act of 2015", regarding all provisions. - Issues related to physician-owned companies that manufacture or distribute medical devices. - Issues relating to cosmetic regulatory reform. - Issues related to 340B payments to hospitals. - Issues related to pseudoephedrine. - Issues related to dextromethorphan. - Issues related to legislation that would modify the Medicare Part B drug reimbursement program. - Issues related to legislation that would establish a rebate in the Medicare Part D program. - Issues related to Pub.L. 108-164, "Fairness to Contact Lens Consumers Act" (FCLCA) and related FTC Contact Lens Rule. - S.2977, "The Medical Electronic Data Technology Enhancement for Consumers' Health" (MEDTECH Act), regarding all provisions. - H.R. 3250, "DXM Abuse Prevention Act of 2015", regarding all provisions. - S. 2994, "DXM Abuse Prevention Act of 2016", regarding all provisions. - S. 1767, "The Combination Products Regulatory Fairness Act of 2015", regarding all provisions. - HR 2646, "Helping Families in Mental Health Crisis Act of 2015", regarding all provisions. - HR 1854, "Comprehensive Justice and Mental Health Act of 2015", regarding all provisions. - S. 1014, "Personal Care Products Safety Act", regarding all provisions. - S. 277, "Contact lens Consumer Health Protection Act of 2016", regarding all provisions. - Issues related to Medicare Part B Demo - Issues related to Expanded Access in Senate Innovation Package
2016 · second_quarter · Alcohol and Drug Abuse
Issues related to the sale of medicines that contain dextromethorphan, including H.R.3250 and S.2994, the DXM Abuse Prevention Act.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · second_quarter · Alcohol and Drug Abuse
Dextromethorphan H.R. 3250/S. 2994, the "DXM Abuse Prevention Act" (DAP) - legislation that would ban the sale of over-the-counter cough and cold medications containing the active ingredient dextromethorphan (DXM) to minors under the age of 18. Additionally, would ban the sale of bulk, unfinished DXM to entities not registered with the U.S. Food and Drug Administration; all sections).
Client expense: $280,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
Client expense: $890,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
Client expense: $2,040,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)